Medical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptoms
Key claim: The FDA is classifying the computerized behavioral therapy device for fibromyalgia symptoms as Class II (special controls), establishing a regulatory pathway intended to assure safety and effectiveness while improving patient access.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the computerized behavioral therapy device for the treatment of fibromyalgia symptoms into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the computerized behavioral therapy device for the treatment of fibromyalgia symptoms. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
Class II classification with special controls creates a clearer regulatory pathway for digital behavioral therapy devices, potentially expanding non-pharmacological treatment options for fibromyalgia patients. For providers and insurers, an established FDA classification can support coverage decisions and clinical adoption of software-based therapeutics in chronic pain care.